GSK’s Tuberculosis Study: A Step Forward in Treatment Innovation

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.

GlaxoSmithKline (GSK) has recently completed a Phase 2A clinical study titled A Parallel Group, Phase 2A, Randomised, Open Label Treatment Study to Assess the Early Bactericidal Activity, Safety and Tolerability of GSK3036656 Administered as a Two Drug Combination With Novel and Established Antitubercular Agents, or Standard of Care in Adults With Rifampicin-susceptible Pulmonary Tuberculosis. The study aimed to evaluate the early bactericidal activity, safety, and tolerability of GSK3036656 in combination with other antitubercular agents over a 14-day period in adults with newly diagnosed drug-sensitive pulmonary tuberculosis.

The interventions tested in this study included GSK3036656 combined with either bedaquiline, delamanid, or BTZ-043, as well as combinations of bedaquiline with delamanid and a standard treatment regimen, RIFAFOUR e-275. These drugs are intended to enhance treatment efficacy against tuberculosis.

The study was designed as a randomized, parallel-group trial with a single-masked approach, where laboratory staff were unaware of treatment assignments. The primary purpose was to assess the early bactericidal activity of the drug combinations.

The study began on May 16, 2022, and the last update was submitted on October 2, 2025. The completion of this study marks a significant step in tuberculosis treatment research.

The successful completion of this study could positively impact GSK’s stock performance by demonstrating progress in tuberculosis treatment, a significant global health issue. This development may also influence investor sentiment positively, especially in comparison to competitors in the pharmaceutical industry focusing on similar treatments.

The study is now completed, and further details can be accessed on the ClinicalTrials portal.